Literature DB >> 25567215

Gentamicin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration (CVVHDF).

Deirdre M D'Arcy1, Owen I Corrigan, Evelyn Deasy, Caitríona M Gowing, Maria B Donnelly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25567215     DOI： 10.1007/s00228-014-1765-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  6 in total

1.  Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen.

Authors:  Etienne de Montmollin; Lila Bouadma; Nathalie Gault; Bruno Mourvillier; Eric Mariotte; Sarah Chemam; Laurent Massias; Emmanuelle Papy; Florence Tubach; Michel Wolff; Romain Sonneville
Journal:  Intensive Care Med       Date:  2014-04-01       Impact factor: 17.440

Review 2.  Approaches for dosage individualisation in critically ill patients.

Authors:  M del Mar Fernández de Gatta; Ana Martin-Suarez; Jose M Lanao
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-07-31       Impact factor: 4.481

Review 3.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients.

Authors:  Nadezda Petejova; Jana Zahalkova; Jana Duricova; Ivana Kacirova; Hana Brozmanova; Karel Urbanek; Milan Grundmann; Arnost Martinek
Journal:  J Chemother       Date:  2012-04       Impact factor: 1.714

5.  Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose.

Authors:  J Gonçalves-Pereira; A Martins; P Póvoa
Journal:  Clin Microbiol Infect       Date:  2009-10-14       Impact factor: 8.067

6.  An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.

Authors:  Deirdre M D'Arcy; Eoin Casey; Caitriona M Gowing; Maria B Donnelly; Owen I Corrigan
Journal:  BMC Pharmacol Toxicol       Date:  2012-11-08       Impact factor: 2.483
  6 in total
  2 in total

1.  Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.

Authors:  Sha He; Zeneng Cheng; Feifan Xie
Journal:  Drug Des Devel Ther       Date:  2022-01-06       Impact factor: 4.162

Review 2.  Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review.

Authors:  Caspar J Hodiamont; Annemieke K van den Broek; Suzanne L de Vroom; Jan M Prins; Ron A A Mathôt; Reinier M van Hest
Journal:  Clin Pharmacokinet       Date:  2022-06-27       Impact factor: 5.577
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.